![](/images/graphics-bg.png)
Daily low-dose oral etoposide for recurrent epithelial ovarian cancer after platinum-based therapy
Joint Authors
Moosavi, A. S.
Jilani, M. Modares
Tehranian, A.
Isfahani, J. Kohpayezadeh
Source
Medical Journal of the Iranian Hospital
Issue
Vol. 6, Issue 2 (31 Jan. 2004), pp.21-25, 5 p.
Publisher
Publication Date
2004-01-31
Country of Publication
United Arab Emirates
No. of Pages
5
Main Subjects
Topics
Abstract EN
The activity and toxicity of etoposide in women with recurrent ovarian cancer are described from a case series of women with recurrent ovarian cancer.
All patients had prior platinum-based chemotherapy and developed progressive disease.
Etoposide was given as 50 mg / day for 21 days every 4 weeks until progression of disease or prohibitive toxicity.
Between December 1999 and april 2001, 12 patients were enrolled in this study.
Ten patients received a total of 48 cycles of etoposide.
Median age was 52 years (28 to 75).
The median number of etoposide cycles was 4 (1 to 11).
There were two partial responses.
The responses lasted 3.5 and 6 months, median Progression Free Interval (PFI) was 7.5 months (5.5 to 11), and median survival time was 8.5 months (1.2 to 21.5).
The major toxicity was leukopenia.
One patient required red blood cell transfusion, and the main nonhematologic toxicity was nausea and vomiting.
Alopecia was universal.
There was no treatment related mortality.
Although etoposide appears to exhibit modest activity in recurrent ovarian cancer after platinum-based therapy, response and survival durations are short.
American Psychological Association (APA)
Moosavi, A. S.& Jilani, M. Modares& Tehranian, A.& Isfahani, J. Kohpayezadeh. 2004. Daily low-dose oral etoposide for recurrent epithelial ovarian cancer after platinum-based therapy. Medical Journal of the Iranian Hospital،Vol. 6, no. 2, pp.21-25.
https://search.emarefa.net/detail/BIM-30602
Modern Language Association (MLA)
Jilani, M. Modares…[et al.]. Daily low-dose oral etoposide for recurrent epithelial ovarian cancer after platinum-based therapy. Medical Journal of the Iranian Hospital Vol. 6, no. 2 (Jan. 2004), pp.21-25.
https://search.emarefa.net/detail/BIM-30602
American Medical Association (AMA)
Moosavi, A. S.& Jilani, M. Modares& Tehranian, A.& Isfahani, J. Kohpayezadeh. Daily low-dose oral etoposide for recurrent epithelial ovarian cancer after platinum-based therapy. Medical Journal of the Iranian Hospital. 2004. Vol. 6, no. 2, pp.21-25.
https://search.emarefa.net/detail/BIM-30602
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references : p. 25
Record ID
BIM-30602